New obesity drug aims to cut side effects with smarter dosing
NCT ID NCT06718998
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 1 trial tested a new drug called NNC0519-0130 in 134 overweight or obese adults. The goal was to see if different ways of increasing the dose could reduce side effects. Participants received weekly or twice-weekly injections for about 24 weeks. The study focused on safety and tolerability, not weight loss.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NNC0519-0130
- What this could lead to
- If successful, this could help find a dosing schedule for NNC0519-0130 that reduces side effects, potentially leading to a better-tolerated weight-loss treatment.
- What could go wrong
- This is an early Phase 1 trial focused on safety and tolerability, not weight loss. The drug may still cause side effects or fail in later studies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Medical University of Graz
Graz, 8010, Austria
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new stomach and gut bypass surgery tackle obesity and diabetes?
- Can a Two-Drug combo tip the scales against obesity?
- Can Weight-Loss surgery change how medications work?
- Coffee grounds probiotic could reshape gut health and fight inflammation
- Can shedding pounds reboot the Heart's exercise engine?
- Can stomach surgery alter how painkillers work?